Seelos Therapeutics, Inc. announced it will collaborate with the Sean M. Healey & AMG Center for ALS in an Expanded Access Program (EAP) that will be fully funded by a grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the ACT for ALS. Under this EAP, Seelos plans to initially enroll 70 patients in a 24-week, open-label study to evaluate SLS-005 in persons with ALS in parallel to its ongoing Phase II/III study on the HEALEY Platform.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.2902 USD | +19.72% | +0.42% | -79.12% |
1st Jan change | Capi. | |
---|---|---|
-79.12% | 3.32M | |
+7.52% | 111B | |
+11.38% | 106B | |
-12.64% | 22.24B | |
+0.44% | 21.25B | |
-4.18% | 18.97B | |
-37.85% | 18.52B | |
-8.58% | 16.81B | |
+37.41% | 12.54B | |
-23.95% | 8.09B |
- Stock Market
- Equities
- SEEL Stock
- News Seelos Therapeutics, Inc.
- Seelos Therapeutics, Inc. to Collaborate with the Healey & AMG Center for ALS in an Expanded Access Program